SAB Biotherapeutics, Inc. (SABSW) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Sioux Falls, SD, United States. El CEO actual es Samuel J. Reich.
SABSW tiene fecha de IPO 2021-10-25, 63 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $238.95K.
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
